| 0 (0%) | 09-27 09:27 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.44 | 1-year : | 3.66 |
| Resists | First : | 2.95 | Second : | 3.13 |
| Pivot price | 2.86  |
|||
| Supports | First : | 2.65 | Second : | 2.2 |
| MAs | MA(5) : | 2.75 |
MA(20) : | 2.87 |
| MA(100) : | 3.14 |
MA(250) : | 3.82 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13.6  |
D(3) : | 11.4 |
| RSI | RSI(14): 37.1 |
|||
| 52-week | High : | 6.16 | Low : | 2.65 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LPCN ] has closed above bottom band by 14.9%. Bollinger Bands are 23.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.78 - 2.8 | 2.8 - 2.82 |
| Low: | 2.64 - 2.66 | 2.66 - 2.68 |
| Close: | 2.7 - 2.73 | 2.73 - 2.76 |
Fri, 26 Sep 2025
Lipocine Seeks Regulatory Clarity on LPCN 2401 Study - TipRanks
Tue, 26 Aug 2025
Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025 - PR Newswire
Tue, 05 Aug 2025
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 - PR Newswire
Fri, 27 Jun 2025
Lipocine begins dosing in Phase III postpartum depression trial of LPCN 1154 - Clinical Trials Arena
Fri, 27 Jun 2025
First Patient Receives Lipocene's LPCN 1154 for Postpartum Depression in Phase 3 Clinical Trial - Patient Care Online
Thu, 22 May 2025
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 5 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 9.8 (%) |
| Shares Short | 88 (K) |
| Shares Short P.Month | 98 (K) |
| EPS | -0.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.19 |
| Profit Margin | -107.2 % |
| Operating Margin | -386.1 % |
| Return on Assets (ttm) | -16.8 % |
| Return on Equity (ttm) | -23.6 % |
| Qtrly Rev. Growth | 595.4 % |
| Gross Profit (p.s.) | 0.77 |
| Sales Per Share | 0.77 |
| EBITDA (p.s.) | -1.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -3.26 |
| PEG Ratio | 0 |
| Price to Book value | 0.85 |
| Price to Sales | 3.51 |
| Price to Cash Flow | -2.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|